| 4.08 0.03 (0.74%) | 06-18 10:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.36 |
1-year : | 6.26 |
| Resists | First : | 4.59 |
Second : | 5.36 |
| Pivot price | 3.92  |
|||
| Supports | First : | 3.94 |
Second : | 3.53 |
| MAs | MA(5) : | 4.08 |
MA(20) : | 4.01 |
| MA(100) : | 4.87 |
MA(250) : | 4.95 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 57.9 |
D(3) : | 54.7 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 6.94 | Low : | 3.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FHTX ] has closed below upper band by 28.5%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.24 - 4.26 | 4.26 - 4.28 |
| Low: | 3.94 - 3.96 | 3.96 - 3.98 |
| Close: | 4.02 - 4.05 | 4.05 - 4.08 |
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Wed, 17 Jun 2026
Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Wed, 17 Jun 2026
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tue, 09 Jun 2026
Foghorn Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Fri, 05 Jun 2026
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Sahm
Fri, 05 Jun 2026
Biotech Foghorn CEO to speak at Goldman Sachs global healthcare event - Stock Titan
Tue, 02 Jun 2026
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Jade Biosciences (JBIO) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 17.9 (%) |
| Held by Institutions | 76.5 (%) |
| Shares Short | 1,470 (K) |
| Shares Short P.Month | 1,360 (K) |
| EPS | -1.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.3 |
| Profit Margin | -266.9 % |
| Operating Margin | -660.4 % |
| Return on Assets (ttm) | -21 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -45.1 % |
| Gross Profit (p.s.) | -0.92 |
| Sales Per Share | 0.48 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -3.51 |
| PEG Ratio | 0 |
| Price to Book value | -3.16 |
| Price to Sales | 8.52 |
| Price to Cash Flow | -2.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|